László Szabó

Dr. László Szabó

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2016 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
UKUsman Khalid
Usman Khalid
EAElijah Ablorsu
Elijah Ablorsu
LSLászló Szabó
László Szabó
RJRobert Jenkins
Robert Jenkins
TBTimothy Bowen
Timothy Bowen
DFDonald J. Fraser
Donald J. Fraser

1 December 2013 in Transplantation Proceedings
Verified
Journal Article
Closed access
DKDávid Ágoston Kovács
Dávid Ágoston Kovács
LLL. Löcsey
L. Löcsey
LSLászló Szabó
László Szabó
RFR. Fedor
R. Fedor
RLR. Laczik
R. Laczik
PSP. Soltész
P. Soltész

1 July 2016 in Transplantation Proceedings
Verified
Journal Article
Closed access
UKUsman Khalid
Usman Khalid
AAA. Asderakis
A. Asderakis
TRT. Rana
T. Rana
LSLászló Szabó
László Szabó
RCR. Chavez
R. Chavez
EAE. Ablorsu
E. Ablorsu

1 July 2010 in Transplantation Proceedings
Verified
Journal Article
Closed access
PDF file
LLL. Löcsey
L. Löcsey
BSB. Szlanka
B. Szlanka
BBB. Borbás
B. Borbás
LSLászló Szabó
László Szabó
ADA. Dán
A. Dán
ILI. Lörincz
I. Lörincz

1 May 2013 in Kidney and Blood Pressure Research
Verified
Journal Article
Open access
RSRéka P. Szabó
Réka P. Szabó
NKNóra Klenk
Nóra Klenk
JBJozsef Balla
Jozsef Balla
LALászló Asztalos
László Asztalos
LSLászló Szabó
László Szabó
ZVZoltán Vokó
Zoltán Vokó
Background/Aims: Patients with a failed kidney transplant represent a unique, high-risk chronic kidney disease population that is increasing in number, and may be sub-optimally managed. Our aim was to compare the survival of patients with failed allografts to patients with native kidney failure and to assess whether their survival is affected by the graft resection. Methods: Kaplan-Meier and Cox-regression survival analyses were performed on the data of 57 patients with graft failure and of 123 transplant-naive haemodialysed patients. Results: After adjustment for age and gender, there was no statistically significant difference in the mortality of patients in the two groups. The 43 patients, who had a transplanted kidney nephrectomy had a statistically not significant survival benefit over non-nephrectomised patients (age and gender adjusted hazard ratio: 0.56 95 % confidence interval: 0.24-1.58, p-value: 0.18). Conclusion: Elective graft resection is a safe, effective alternative for both the treatment and the prevention of the chronic inflammatory state associated with a failed kidney transplant.

1 June 2016 in Orvosi Hetilap
Verified
Journal Article
Closed access
BNBalázs Nemes
Balázs Nemes
RFRoland Fedor
Roland Fedor
ZKZsolt Kanyári
Zsolt Kanyári
L†Lajos †Lőcsey
Lajos †Lőcsey
FJFerenc Juhász
Ferenc Juhász
LALászló Asztalos
László Asztalos
Introduction: The first renal transplantation was completed in 1991 at the University of Debrecen. In 2013 Hungary joined Eurotransplant. Aim: The authors retrospectively compared the trends. Method: Comparison between Period A (from January 1, 2008 to August 31, 2013) and Period B (from September 1, 2013 to October 22, 2015). Results: The proportion of living transplants rose from 3.5% to 9.1 %. During period B over 25% of utilized donors were over 60 years of age. Recipients with body mass index above 30 kg/m2 increased from 12% to 31%. Prevalence of diabetes among recipients rose twofold. Uretero-neocystostomy was used during period A (99%) while in period B end to side uretero-ureteral anastomosis has also gained popularity (68%). In 2013 the authors introduced routine use of induction treatment. Acute rejection rate decreased from 34% to 8%. The rate of surgical complications did not change. Acute bacterial infections decreased from 41% to 33%. Cumulative renal allograft 1, 3 and 5 year survival rates were 86.6%, 85% and 82.7% in group A vs. projected rates 88%, 84% and 84% in group B, respectively. Conclusions: Despite the growing proportion of expanded criteria donors, the authors were able to maintain a low incidence of delayed graft function and a favorable graft survival. Since 2013 the authors introduced treatments for acute humoral rejection according to international standards. Orv. Hetil., 2016, 157(24), 925–937.